Oral antiviral candidate for influenza A to treat outpatients
Official title: Advancing a novel oral anti-IAV therapeutic to the clinic
Funded at Stanford University · NIH-11563772 · Data updated 2026-11-12
A new oral antiviral pill for flu A is being developed to be easy to take at home and to work differently from existing drugs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 11, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,265,732 |
| NIH project number | 1R56AI193005-01A1 |
| Project ID | NIH-11563772 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with or at risk of influenza A infection who could participate in future clinical development.
✕Less likely to help
Early-stage animal studies mean this grant does not yet involve patients in trials; it may not benefit people without influenza A.
What this research studies
This project aims to create a small, orally available antivirus that works through a unique mechanism against influenza A. It uses animal studies to show proof of concept and guides the selection of a development candidate and backups. If successful, it could lead to a new outpatient treatment option that complements current flu therapies.
Why it matters
Potential benefit: If successful, patients with flu A could have a convenient, effective outpatient treatment option.
How similar studies have gone: Preclinical data in mice show strong protection, supporting potential translation to humans.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Glenn, Jeffrey S — Stanford University
- Study coordinator: Glenn, Jeffrey S
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.